<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20250207</date><key>collection.key</key><document><id>PMC9314880</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.3389/fneur.2022.899849</infon><infon key="article-id_pmc">PMC9314880</infon><infon key="elocation-id">899849</infon><infon key="kwd">deep vein thrombosis inflammation intracerebral hemorrhage leukocytes elderly</infon><infon key="license">This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</infon><infon key="name_0">surname:Wang;given-names:Gang</infon><infon key="name_1">surname:Zhao;given-names:Wenjun</infon><infon key="name_2">surname:Zhao;given-names:Zhiyong</infon><infon key="name_3">surname:Wang;given-names:Dengfeng</infon><infon key="name_4">surname:Wang;given-names:Dong</infon><infon key="name_5">surname:Bai;given-names:Ruobing</infon><infon key="name_6">surname:Hou;given-names:Boru</infon><infon key="name_7">surname:Ren;given-names:Haijun</infon><infon key="section_type">TITLE</infon><infon key="type">front</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>0</offset><text>Leukocyte as an Independent Predictor of Lower-Extremity Deep Venous Thrombosis in Elderly Patients With Primary Intracerebral Hemorrhage</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>138</offset><text>Objective</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>148</offset><text>Due to the interaction of leukocytes with platelets and coagulation factors, they may in turn play a role in hemostasis or the formation of thrombi. This study aimed to investigate the association of leukocytosis on admission with an increased risk of acute lower-extremity deep venous thrombosis (LEDVT) in elderly patients with primary intracerebral hemorrhage (ICH).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>518</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>526</offset><text>This was a single-center, retrospective observational study of consecutive patients observed with spontaneous ICH aged 60 years or above at Lanzhou University Second Hospital from January 2017 to September 2021. Clinical data and demographic information were collected and analyzed. Univariate and multivariate analyses were conducted to identify independent risk factors of acute LEDVT. One-to-one matching was implemented to balance important patient characteristics by the groups' propensity score matching (PSM) analysis.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1052</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1060</offset><text>A total of 371 elderly patients with primary ICH fulfilled requirements for inclusion and exclusion, of whom 33 (8.89%) experienced LEDVT. Leukocyte counts were statistically higher in the LEDVT group compared to the non-LEDVT group [12.89 (8.80â14.61) Ã 109 cells/L vs. 8.31 (6.60â10.75) Ã 109 cells /L, p &lt; 0.001]. Multivariate logistic regression models adjusted for several potential confounding factors were performed, and leukocytes were consistently a significant independent predictor of LEDVT. The optimal cut-off value of leukocyte counts calculated from the receiver operating characteristic (ROC) curve to predict LEDVT was 10.22 Ã 109 cells /L (area under the curve:0.714, 95%CI 0.665â0.759; the sensitivity was 72.73%; the specificity was 71.01%) in elderly patients with primary ICH. After one-to-one PSM, compared to the matched non-LEDVT group, the matched LEDVT group had significantly higher leukocyte counts [11.98 (8.40â13.94) Ã 109 cells/L vs. 6.12 (4.68â12.00) Ã 109 cells/L, p = 0.003]. After PSM, the ROC curve was plotted for leukocytes as a predictor of LEDVT, with an AUC of 0.722 (95%CI 0.593â0.828, p = 0.001; the sensitivity was 87.10%, and the specificity was 61.29%). Elevated leukocytes remained independently significant as predictors of LEDVT in elderly patients with primary ICH.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>2394</offset><text>Conclusion</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>2405</offset><text>Leukocyte at admission is an independent risk factor of LEDVT in elderly patients with primary ICH.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2505</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2518</offset><text>Spontaneous intracerebral hemorrhage (ICH) is a devastating cerebrovascular disease with high morbidity, disability, and mortality. Deep venous thrombosis (DVT) is a common but elusive illness that can lead to long-term disability or death, and DVT mainly occurs in the paralyzed lower extremities after ICH. The incidence of post-stroke lower-extremity deep venous thrombosis (LEDVT) varies widely, from 10 to 75%, depending on the diagnosis method and the evaluation timing. It is undeniable that LEDVT incidence is higher in acute spontaneous ICH than that in ischemic stroke. The literature has identified a series of risk factors that can predict LEDVT in ICH patients, including older age, paralysis, a history of deep vein puncture, immobilization, infection, and laboratory characteristics. Elderly patients with acute neurological illness, including acute ICH, are at high risk for LEDVT due to their increased prevalence of obesity, increased disease frequency, prolonged immobility, and increased levels of procoagulants without a corresponding increase in anticoagulants. The detailed mechanism responsible for LEDVT in elderly patients with primary ICH is yet to be elaborated.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3709</offset><text>The leading laboratory test indicators to predict LEDVT are D-dimer, blood routine, and blood lipids. In recent years, the association of inflammatory biomarkers with LEDVT has become a research focus. Elevated inflammation indicators in critical illness, including spontaneous ICH, were considered independent risk factors for acute LEDVT patients, such as platelet to lymphocyte ratios and neutrophil-lymphocyte ratios. Acute leukocytosis is a well-established phenomenon in ICH. Andrea et al. demonstrated that leukocytes were essential for regulating the coagulation cascade after acute ICH. Leukocytes interact with platelets and endothelial cells, and coagulation factors have been widely recognized as essential for promoting hemostasis under physiological and pathological conditions. An acute leukocytosis may shift the hemostatic balance in favor of coagulation, thereby arresting bleeding after ICH. However, no study has examined the association between leukocytes and LEDVT in elderly patients with primary ICH.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4734</offset><text>Therefore, this study aimed to assess the incidence and risk factors associated with LE DVT in elderly patients with primary ICH and further analyze the correlation between leukocytes and LEDVT for early clinical prevention.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>4959</offset><text>Materials and Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>4981</offset><text>Study Population</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>4998</offset><text>This was a single-center, retrospective observational study of consecutive patients presenting with spontaneous ICH aged 60 years or above at Lanzhou University Second Hospital from January 2017 to September 2021. Our local Ethics Committee approved the study. Patients were eligible, if (1) diagnoses of ICH required confirmation by computed tomography (CT) scan within 48 h after admission; (2) peripheral blood samples were obtained through venipuncture upon admission; (3) the diagnosis of LEDVT was confirmed by Doppler ultrasonography. Exclusion criteria were listed as follows: (1) age &lt; 60 years; (2) diagnoses with secondary ICH, including aneurysm, arteriovenous malformation, Moyamoya disease, brain tumor, and hemorrhagic infarction; (2) primary intraventricular hemorrhage (IVH); (3) historical stroke; and (4) history of DVT or pulmonary embolism (PE), history of thrombophilia.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>5891</offset><text>Baseline Data Collection</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>5916</offset><text>Patients' demographic information, medical history, diagnostic information, laboratory data, length of intensive care unit (ICU) stay, intervening measures (conservative therapy and surgery), and comorbidities at the hospital (pulmonary infection) were collected via an electronic medical record system. Peripheral venous blood was obtained by venous puncture within 1 h of admission for laboratory examinations, including blood routine, blood biochemical indexes, D-dimer, and blood coagulation. Leukocyte counts (reference range, 3.5 Ã 109 cells/L to 9.5 Ã 109 cells/L) and hemoglobin (reference range, 115â150 g/L) were collected from the blood routine test. ICH hematoma volume was measured on the initial CT using the ABC/2 method. ICH location on admission CT scan was grouped into 2 categories, namely, patients with lobar ICH and those with deep ICH. Hematoma locations at the cortical and subcortical junction were defined as lobar ICH, while those involving the thalamus, basal ganglia, brainstem, and cerebellum were described as deep ICH.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>6971</offset><text>Pulmonary infection was defined as an episode of infection that occurred more than 48 h after hospital admission. According to the previous literature, the pulmonary infection can be diagnosed clinically, microbiologically, and radiologically.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7215</offset><text>Diagnosis of LEDVT</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7234</offset><text>Color Doppler ultrasonography was routinely performed once weekly for patients admitted to the neurological ICU, every 2 weeks for patients admitted to the neurosurgery unit, and as indicated for patients with signs and symptoms of LEDVT (e.g., swelling and pain). In patients with signs or symptoms, LEDVT was diagnosed by complete ultrasound with Doppler waveforms and images from thigh to ankle, and based on lower extremity ultrasonography showing incompressible distal or proximal veins. When the deep vein was completely embolized, no blood flow was detected at the lesion, and the distal blood flow did not increase when squeezed. The probe detected the blood flow signal filling the defect when the deep vein was partially embolized. A small blood flow was visible only after squeezing the distal limb.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8045</offset><text>The Caprini risk assessment score was utilized to strengthen the observance of venous thromboembolism prophylactic regimens for patients under both medical and surgical conditions and accordingly identify the required thromboprophylaxis mode. Prevention of venous thrombosis, including LEDVT, such as getting out of bed, is based on the Caproni score. A lower-extremity pneumatic pump was used to prevent LEDVT. Low-dose subcutaneous heparin (100 U/kg, QD) was used to prevent deep vein thrombosis. Low-molecular-weight heparin (100 U/kg, Q12H) was applied in primary ICH patients with acute LEDVT as soon as the venous Doppler ultrasound confirmed the diagnosis.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8709</offset><text>Statistical Analysis</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8730</offset><text>All statistical analyses were conducted with the SPSS software (version 25.0, IBM SPSS, IBM Corp, USA), Prism 8.3.0 (GraphPad Software, San Diego, CA, USA), and MedCalc version 20.0.4 (MedCalc Software, Ostend, Belgium). The Ï2 test, Fisher's exact test, and the Mann-Whitney U test were compared. The box plots graph represents the median with an interquartile range (IQR). For correlation analysis, Spearman's correlation was applied. All variables with p &lt; 0.10 in univariable analysis were selected for the multivariate logistic regression to evaluate independent risk factors. The multivariate logistic regression models were used to determine the relationship of leukocytes with LEDVT. Model 1 was unadjusted. Model 2 was adjusted by baseline GCS, leukocyte counts, baseline volume, length of ICU stay, treatment, pulmonary infection, and prophylactic use of low-dose subcutaneous heparin. Model 3 = Model 2 and adjusted by neutrophils. We constructed the receiver operating characteristic (ROC) curve and calculated the area under the ROC curve (AUC) to access the predictive power of leukocytes for LEDVT. To match baseline characteristics, propensity score matching (PSM) analysis was performed to obtain a 1:1 nearest-neighbor matching, with a match tolerance of 0.01. Variables with statistical significance (p &lt; 0.05) in the univariate analysis were included in the matching. A two-sided p&lt; 0.05 was determined to be statistically significant.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>10188</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>10196</offset><text>Baseline Characteristics of the Study Patients</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>10243</offset><text>The study flow is documented in Figure 1. A total of 371 elderly patients with primary ICH fulfilled requirements for both inclusion and exclusion, of whom 33 (8.89%) experienced LEDVT, 22 distal DVTs (66.67%), 9 mixed DVTs (27.27%), and 2 proximal DVTs (6.06%) (Figure 2A). Figure 2B illustrates the distribution, number, and percentage of LEDVT relative to the location of ICH hematoma. In the LEDVT group, pulmonary embolism occurred in four cases. The cumulative LEDVT rate using Kaplan-Meier analysis from ICH onset to LEDVT is displayed in Figure 2C. The time from ICH onset to LEDVT was 13.0 (IQR,8.50â18.0) days. The median leukocyte counts were [8.57 (IQR 6.77â11.37), Ã 109 cells/L]. The baseline GCS score was 11 (IQR, 8.0â13.0), and the initial ICH volume was 14.15 ml (IQR, 4.93â35.76 ml). A total of 224 patients (60.4%) were treated conservatively, and 147 patients (39.6%) had surgery.</text></passage><passage><infon key="file">fneur-13-899849-g0001.jpg</infon><infon key="id">F1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>11154</offset><text>Flowchart of the study. LEDVT, lower-extremity deep venous thrombosis; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; ICU, intensive care unit. *p &lt; 0.05.</text></passage><passage><infon key="file">fneur-13-899849-g0002.jpg</infon><infon key="id">F2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>11318</offset><text>LEDVT overall. (A) Pie chart showing the number and percentage of the three types of LEDVT. (B) Pie chart demonstrating the distribution, number, and percentage of LEDVT relative to the location of intracerebral hemorrhage hematoma. (C) Cumulative LEDVT rate using Kaplan-Meier analysis from intracerebral hemorrhage onset to LEDVT. LEDVT, lower-extremity deep venous thrombosis.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>11698</offset><text>Correlation Between Peripheral Blood Leukocyte Counts and Initial Clinical Status at Admission</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>11793</offset><text>The results of correlation analysis demonstrated that leukocyte was positively correlated with the initial ICH volume (r = 0.2396, 95%CI 0.1383 to 0.3360, p &lt; 0.001, Figure 3A) and negatively correlated with the baseline GCS score (r = â0.2513, 95%CIâ0.3470 toâ0.1505, p &lt; 0.001, Figure 3B).</text></passage><passage><infon key="file">fneur-13-899849-g0003.jpg</infon><infon key="id">F3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>12091</offset><text>Correlation between peripheral blood leukocyte counts and initial clinical status at admission. (A) Scatterplot of expression correlation between leukocyte counts and baseline volume. (B) Scatterplot of expression correlation between leukocyte counts and baseline Glasgow Coma Scale score.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>12381</offset><text>Association of Peripheral Blood Leukocyte Counts With LEDVT</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>12441</offset><text>Univariate and multivariate analyses were conducted to identify independent predictors of LEDVT in elderly patients with primary ICH. Demographic and clinical features between Non-LEDVT and LEDVT groups were compared, as depicted in Table 1. Baseline GCS score (p &lt; 0.001), baseline ICH volume (p = 0.005), length of ICU stays (p = 0.007), surgery (p &lt; 0.001), pulmonary infection (p &lt; 0.001), neutrophils (p = 0.004), prophylactic use of low-dose subcutaneous heparin (p &lt; 0.001), and leukocyte (p &lt; 0.001) were found to have a statistically significant association with the occurrence of LEDVT in elderly patients with primary ICH. Leukocyte counts were statistically higher in the LEDVT group compared to the non-LEDVT group [12.89 (8.80â14.61) Ã 109 cells/L vs. 8.31 (6.60â10.75) Ã 109 cells/L, p &lt; 0.001; Table 1; Figure 4A]. Leukocytes were positively associated with the occurrence of LEDVT with an OR value of 1.184 [95% confidence interval (CI) 1.091â1.284, p &lt; 0.001) in the unadjusted model (Model 1, Table 2). The odds ratios (ORs) were adjusted for all outcomes on the baseline GCS, leukocyte counts, baseline volume, length of ICU stay, treatment, pulmonary infection, prophylactic use of low-dose subcutaneous heparin, and neutrophils. After adjustment in the multivariate model (Model 2, Table 2), leukocyte [OR 1.151, 95%CI 1.047â1.265, p = 0.004], treatment (surgery) (OR 0.312, 95%CI 0.106â0.923, p = 0.035), and pulmonary infection (OR 0.119, 95% CI 0.026â0.550, p = 0.006) were statistically associated with LEDVT (Table 2; Figure 4B). The forest plot (Figure 4B) displays that the leukocyte was an independent risk factor for LEDVT in elderly patients with primary ICH. The optimal cut-off value of leukocyte counts calculated by the ROC curve to predict LEDVT was 10.22 Ã 109/L (AUC:0.714, 95%CI 0.665â0.759, p &lt; 0.001; the sensitivity was 72.73%, and the specificity was 71.01%; Figure 4C) in elderly patients with primary ICH. To explore the relationship between neutrophils and LEDVT, neutrophils were included in a multivariate analysis model (Model 3 = Model 2 + neutrophils, Table 3). Interestingly, leukocytes remained associated with the occurrence of LEDVT. Overall, leukocytes were positively associated with the occurrence of LEDVT with an OR of 1.184 (95%CI 1.091-1.284), 1.151 (95%CI 1.047â1.265), and 1.483 (95%CI 1.092â2.014) in Model 1, Model 2, and Model 3, respectively.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>14874</offset><text> Univariate analysis of association with LEDVT before and after propensity-score matching in spontaneous intracerebral hemorrhage patients.</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Characteristics&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; colspan=&quot;3&quot; style=&quot;border-bottom: thin solid #000000;&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Before propensity-score matching&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; colspan=&quot;3&quot; style=&quot;border-bottom: thin solid #000000;&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;After propensity-score matching&lt;/bold&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Non-LEDVT&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;LEDVT&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Non-LEDVT&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;LEDVT&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;&lt;italic&gt;P&lt;/italic&gt; value&lt;/bold&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;(&lt;italic&gt;N&lt;/italic&gt; = 338)&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;(&lt;italic&gt;N&lt;/italic&gt; = 33)&lt;/bold&gt;
&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;(&lt;italic&gt;N&lt;/italic&gt; = 31)&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;(&lt;italic&gt;N&lt;/italic&gt; =31)&lt;/bold&gt;
&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Age, yrs, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;67.0 (64.0â72.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;68.0 (63.0â72.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.557&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;68.0 (63.0â75.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;67.0 (63.0â71.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.425&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;bold&gt;Gender&lt;/bold&gt; (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.951&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Male&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;203 (60.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20 (60.6)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;21 (67.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;20 (64.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.788&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Female&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;135 (39.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;13 (39.4)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (32.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11 (35.5)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; colspan=&quot;7&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Medical history&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hypertension (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;228 (67.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24 (72.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.536&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 (83.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;22 (71.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.224&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Diabetes (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;61 (18.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (15.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.678&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8 (25.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (16.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.349&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Smoking (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;33 (9.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (15.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.330&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (16.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (16.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.000&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Alcohol (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;36 (10.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (15.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.431&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6 (19.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (12.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.490&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prior anticoagulation or antiplatelet therapy (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 (7.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4 (12.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.373&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (9.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (9.7)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.000&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; colspan=&quot;7&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Admission vital signs&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Systolic blood pressure, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;156 (147â170)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;156 (150â162.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.987&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;159.0 (151.0â170.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;156.0 (150â162.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.278&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Diastolic blood pressure, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;89 (78â98)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;86 (79.50â98)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.864&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;89.0 (82.0â102.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;86.0 (80.0â96.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.714&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Time from symptom onset to initial CT, hours, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.0 (3.0â5.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.0 (3.0â5.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.228&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.0 (3.0â5.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.0 (3.0â5.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.756&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Baseline Glasgow coma score, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11.0 (9.0â14.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.0 (7.0â11.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.0 (7.0â11.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9.0 (7.0â11.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.570&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Baseline volume, ml, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12.64 (4.32â34.10)64(&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;(27.36 (14.43â47.82)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.00.00505&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29.34 (12.50â38.54)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25.86 (13.78â49.17)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.741&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Presence of intraventricular hemorrhage (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;83 (24.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11 (33.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.269&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (32.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10 (32.3)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.000&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ICH location (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.141&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.279&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lobar&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;63 (18.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (9.1)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6 (19.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3 (9.7)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Deep&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;275 (81.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 (90.9)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25 (80.6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;28 (90.3)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; colspan=&quot;7&quot; rowspan=&quot;1&quot;&gt;
&lt;bold&gt;Admission laboratory&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Leukocyte counts ,10&lt;sup&gt;9&lt;/sup&gt;cells/L, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.31 (6.60â10.75)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;12.89 (8.80â14.61)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.12 (4.68â12.00)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11.98 (8.40â13.94)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.003&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neutrophils counts,10&lt;sup&gt;9&lt;/sup&gt;cells/L, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6.86 (4.79â9.37)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.17 (5.80â12.77)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.004&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.49 (3.47â10.67)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;10.12 (5.59â12.05)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.042&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hemoglobin, g/L, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;148.50 (136.0â162.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;150.0 (137.0â159.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.979&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;148.0 (129.0â162.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;150.0 (136.0â161.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.725&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Platelet,10&lt;sup&gt;9&lt;/sup&gt;/L, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;162.50 (124.0â200.25)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;155.0 (105.50â196.50)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.391&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;129.0 (100.0â170.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;155.0 (103.0â196.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.248&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prothrombin time, seconds, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11.40 (11.00â12.13)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11.40 (10.90â11.95)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.383&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11.50 (11.20â11.90)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;11.30 (10.80â12.00)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.212&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;International normalized ratio, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.02 (0.95â1.08)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.01 (0.96â1.08)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.754&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.02 (0.98â1.06)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.00 (0.96â1.08)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.464&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Activated partial thromboplastin time, seconds, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25.30 (21.50â28.83)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25.60 (21.35â30.40)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.742&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;25.20 (22.20â30.40)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24.40 (21.20â30.30)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.714&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Fibrinogen, g/L, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.0 (2.50â3.51)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.89 (2.47â3.60)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.805&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;3.04 (2.70â3.70)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.90 (2.44â3.60)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.382&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Dâdimer, ug/ml, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.57 (0.3â1.13)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.78 (0.37â1.80)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.119&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.60 (0.27â0.99)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.72 (0.36â1.54)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.210&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Length of ICU stay, days, median (IQR)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0 (0.0â4.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5.0 (0.0â14.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.007&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;8.0 (0.0â15.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.0 (0.0â14.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.228&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prophylactic use of low-dose subcutaneous heparin, (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;30 (8.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (21.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;9 (29.0)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;6 (19.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.374&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Treatment&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.520&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Conservative therapy (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;217 (64.2)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (21.2)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;5 (16.1)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;7 (22.6)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Surgery (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;121 (35.8)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 (78.8)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;26 (83.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;24 (77.4)&lt;/td&gt;&lt;td rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pulmonary infection (&lt;italic&gt;N&lt;/italic&gt;, %)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;177 (52.4)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;31 (93.9)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29 (93.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;29 (93.5)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.000&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>15014</offset><text>Characteristics	Before propensity-score matching	After propensity-score matching	 		Non-LEDVT	LEDVT	P value	Non-LEDVT	LEDVT	P value	 		(N = 338)	(N = 33)		(N = 31)	(N =31)		 	Age, yrs, median (IQR)	67.0 (64.0â72.0)	68.0 (63.0â72.0)	0.557	68.0 (63.0â75.0)	67.0 (63.0â71.0)	0.425	 	Gender (N, %)			0.951				 	Male	203 (60.1)	20 (60.6)		21 (67.7)	20 (64.5)	0.788	 	Female	135 (39.9)	13 (39.4)		10 (32.3)	11 (35.5)		 	Medical history	 	Hypertension (N, %)	228 (67.5)	24 (72.7)	0.536	26 (83.9)	22 (71.0)	0.224	 	Diabetes (N, %)	61 (18.0)	5 (15.2)	0.678	8 (25.8)	5 (16.1)	0.349	 	Smoking (N, %)	33 (9.8)	5 (15.2)	0.330	5 (16.1)	5 (16.1)	1.000	 	Alcohol (N, %)	36 (10.7)	5 (15.2)	0.431	6 (19.4)	4 (12.9)	0.490	 	Prior anticoagulation or antiplatelet therapy (N, %)	26 (7.7)	4 (12.1)	0.373	3 (9.7)	3 (9.7)	1.000	 	Admission vital signs	 	Systolic blood pressure, median (IQR)	156 (147â170)	156 (150â162.5)	0.987	159.0 (151.0â170.0)	156.0 (150â162.0)	0.278	 	Diastolic blood pressure, median (IQR)	89 (78â98)	86 (79.50â98)	0.864	89.0 (82.0â102.0)	86.0 (80.0â96.0)	0.714	 	Time from symptom onset to initial CT, hours, median (IQR)	4.0 (3.0â5.0)	4.0 (3.0â5.0)	0.228	5.0 (3.0â5.0)	4.0 (3.0â5.0)	0.756	 	Baseline Glasgow coma score, median (IQR)	11.0 (9.0â14.0)	9.0 (7.0â11.0)	&lt;0.001	8.0 (7.0â11.0)	9.0 (7.0â11.0)	0.570	 	Baseline volume, ml, median (IQR)	12.64 (4.32â34.10)64(	(27.36 (14.43â47.82)	0.00.00505	29.34 (12.50â38.54)	25.86 (13.78â49.17)	0.741	 	Presence of intraventricular hemorrhage (N, %)	83 (24.6)	11 (33.3)	0.269	10 (32.3)	10 (32.3)	1.000	 	ICH location (N, %)			0.141			0.279	 	Lobar	63 (18.6)	3 (9.1)		6 (19.4)	3 (9.7)		 	Deep	275 (81.4)	30 (90.9)		25 (80.6)	28 (90.3)		 	Admission laboratory	 	Leukocyte counts ,109cells/L, median (IQR)	8.31 (6.60â10.75)	12.89 (8.80â14.61)	&lt;0.001	6.12 (4.68â12.00)	11.98 (8.40â13.94)	0.003	 	Neutrophils counts,109cells/L, median (IQR)	6.86 (4.79â9.37)	10.17 (5.80â12.77)	0.004	4.49 (3.47â10.67)	10.12 (5.59â12.05)	0.042	 	Hemoglobin, g/L, median (IQR)	148.50 (136.0â162.0)	150.0 (137.0â159.0)	0.979	148.0 (129.0â162.0)	150.0 (136.0â161.0)	0.725	 	Platelet,109/L, median (IQR)	162.50 (124.0â200.25)	155.0 (105.50â196.50)	0.391	129.0 (100.0â170.0)	155.0 (103.0â196.0)	0.248	 	Prothrombin time, seconds, median (IQR)	11.40 (11.00â12.13)	11.40 (10.90â11.95)	0.383	11.50 (11.20â11.90)	11.30 (10.80â12.00)	0.212	 	International normalized ratio, median (IQR)	1.02 (0.95â1.08)	1.01 (0.96â1.08)	0.754	1.02 (0.98â1.06)	1.00 (0.96â1.08)	0.464	 	Activated partial thromboplastin time, seconds, median (IQR)	25.30 (21.50â28.83)	25.60 (21.35â30.40)	0.742	25.20 (22.20â30.40)	24.40 (21.20â30.30)	0.714	 	Fibrinogen, g/L, median (IQR)	3.0 (2.50â3.51)	2.89 (2.47â3.60)	0.805	3.04 (2.70â3.70)	2.90 (2.44â3.60)	0.382	 	Dâdimer, ug/ml, median (IQR)	0.57 (0.3â1.13)	0.78 (0.37â1.80)	0.119	0.60 (0.27â0.99)	0.72 (0.36â1.54)	0.210	 	Length of ICU stay, days, median (IQR)	0.0 (0.0â4.0)	5.0 (0.0â14.0)	0.007	8.0 (0.0â15.0)	0.0 (0.0â14.0)	0.228	 	Prophylactic use of low-dose subcutaneous heparin, (N, %)	30 (8.9)	7 (21.2)	&lt;0.001	9 (29.0)	6 (19.4)	0.374	 	Treatment			&lt;0.001			0.520	 	Conservative therapy (N, %)	217 (64.2)	7 (21.2)		5 (16.1)	7 (22.6)		 	Surgery (N, %)	121 (35.8)	26 (78.8)		26 (83.9)	24 (77.4)		 	Pulmonary infection (N, %)	177 (52.4)	31 (93.9)	&lt;0.001	29 (93.5)	29 (93.5)	1.000	 	</text></passage><passage><infon key="file">T1.xml</infon><infon key="id">T1</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>18463</offset><text>CT, computed tomography; LEDVT, lower-extremity deep venous thrombosis; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; IQR, Interquartile range; ICU, intensive care unit.</text></passage><passage><infon key="file">fneur-13-899849-g0004.jpg</infon><infon key="id">F4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>18643</offset><text>Association of peripheral blood leukocyte counts with LEDVT. (A) Comparison of leukocyte counts between Non-LEDVT and LEDVT groups. (B) Forest plot of multivariate analysis for risk factors associated with LEDVT. (C) Receiver operating curve analysis of leukocyte counts for predicting LEDVT. The optimal cutoff value for leukocyte counts as a predictor for LEDVT in primary intracerebral hemorrhage patients was determined to be 10.22 Ã 109 U/L (AUC was 0.714, the sensitivity was 72.73%, and the specificity was 71.01%). (D) Comparison of leukocyte counts between non-LEDVT and LEDVT groups after propensity-score matching. (E) The area under the curve of leukocytes for LEDVT was 0.722 with a sensitivity of 87.10% and a specificity of 61.29%. A median with the interquartile range was shown for box plots graph in panel A and panel D. Groups were compared using Mann-Whitney U tests. Correlations were determined using Spearman's correlation analysis (*p&lt; 0.05). LEDVT, lower-extremity deep venous thrombosis; LSH, low-dose subcutaneous heparin; OR, Odds ratios; CI, Confidence interval.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>19736</offset><text> Predictors for LEDVT of spontaneous intracerebral hemorrhage in the multivariate model.</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; colspan=&quot;4&quot; style=&quot;border-bottom: thin solid #000000;&quot; rowspan=&quot;1&quot;&gt;&lt;bold&gt;(Model 1)&lt;/bold&gt;&lt;sup&gt;&lt;bold&gt;a&lt;/bold&gt;&lt;/sup&gt;
&lt;bold&gt;Unadjusted OR (95%CI)&lt;/bold&gt;&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; colspan=&quot;4&quot; style=&quot;border-bottom: thin solid #000000;&quot; rowspan=&quot;1&quot;&gt;&lt;bold&gt;(Model 2)&lt;/bold&gt;&lt;sup&gt;&lt;bold&gt;a&lt;/bold&gt;&lt;/sup&gt;
&lt;bold&gt;AdjustedAOR (95%CI)&lt;/bold&gt;&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Independent variable&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;OR&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Lower&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Upper&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;&lt;italic&gt;P&lt;/italic&gt;-value&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;OR&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Lower&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Upper&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;&lt;italic&gt;P&lt;/italic&gt;-value&lt;/bold&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Baseline GCS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.821&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.729&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.923&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.970&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.798&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.178&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.757&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Leukocyte&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.184&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.091&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.284&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.151&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.047&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.265&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.004*&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Baseline volume&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.017&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.003&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.031&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.015&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.989&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.965&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.014&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.399&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Length of ICU stay&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.112&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.058&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.168&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.044&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.976&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.126&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.272&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Treatment (surgery)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.150&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.063&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.356&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.312&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.106&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.923&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.035*&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pulmonary infection&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.071&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.017&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.301&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&amp;lt;0.001&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.119&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.026&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.550&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.006*&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prophylactic use of low-dose subcutaneous heparin&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.362&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.145&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.903&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.029&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.216&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.344&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.290&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.762&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>19825</offset><text>	(Model 1)aUnadjusted OR (95%CI)	(Model 2)aAdjustedAOR (95%CI)	 	Independent variable	OR	Lower	Upper	P-value	OR	Lower	Upper	P-value	 	Baseline GCS	0.821	0.729	0.923	0.001	0.970	0.798	1.178	0.757	 	Leukocyte	1.184	1.091	1.284	&lt;0.001	1.151	1.047	1.265	0.004*	 	Baseline volume	1.017	1.003	1.031	0.015	0.989	0.965	1.014	0.399	 	Length of ICU stay	1.112	1.058	1.168	&lt;0.001	1.044	0.976	1.126	0.272	 	Treatment (surgery)	0.150	0.063	0.356	&lt;0.001	0.312	0.106	0.923	0.035*	 	Pulmonary infection	0.071	0.017	0.301	&lt;0.001	0.119	0.026	0.550	0.006*	 	Prophylactic use of low-dose subcutaneous heparin	0.362	0.145	0.903	0.029	1.216	0.344	4.290	0.762	 	</text></passage><passage><infon key="file">T2.xml</infon><infon key="id">T2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>20465</offset><text>aAdjusted covariates: Model 1: unadjusted; Model 2: baseline GCS, leukocyte counts, baseline volume, length of ICU stay, treatment, pulmonary infection, and prophylactic use of low-dose subcutaneous heparin. CI, Confidence interval; LEDVT, lower-extremity deep venous thrombosis; GCS, Glasgow Coma Scale; ICU, intensive care unit; OR, Odds ratios. *p &lt; 0.05.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>20824</offset><text>Predictors for LEDVT of spontaneous intracerebral hemorrhage in the multivariate model.</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; colspan=&quot;2&quot; style=&quot;border-bottom: thin solid #000000;&quot; rowspan=&quot;1&quot;&gt;&lt;bold&gt;(Model 3)&lt;/bold&gt;
&lt;sup&gt;&lt;bold&gt;a&lt;/bold&gt;&lt;/sup&gt;&lt;bold&gt;Adjusted&lt;/bold&gt;&lt;break/&gt;
&lt;bold&gt;AOR (95%CI)&lt;/bold&gt;&lt;/th&gt;&lt;th rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Independent variable&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;OR&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Lower&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Upper&lt;/bold&gt;
&lt;/th&gt;&lt;th valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;&lt;italic&gt;P&lt;/italic&gt;-value&lt;/bold&gt;
&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Baseline GCS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.991&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.813&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.207&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.926&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Leukocyte&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.483&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.092&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2.014&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.012*&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Neutrophils&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.770&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.572&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.036&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.084&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Baseline volume&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.991&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.966&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.016&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.469&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Length of ICU stay&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.044&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.967&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.127&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.273&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Treatment (surgery)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.322&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.107&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.966&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.043*&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pulmonary infection&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.113&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.024&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.531&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.006*&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prophylactic use of low-dose subcutaneous heparin&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;1.241&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.346&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;4.454&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;0.740&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>20912</offset><text>		(Model 3)aAdjustedAOR (95%CI)		 	Independent variable	OR	Lower	Upper	P-value	 	Baseline GCS	0.991	0.813	1.207	0.926	 	Leukocyte	1.483	1.092	2.014	0.012*	 	Neutrophils	0.770	0.572	1.036	0.084	 	Baseline volume	0.991	0.966	1.016	0.469	 	Length of ICU stay	1.044	0.967	1.127	0.273	 	Treatment (surgery)	0.322	0.107	0.966	0.043*	 	Pulmonary infection	0.113	0.024	0.531	0.006*	 	Prophylactic use of low-dose subcutaneous heparin	1.241	0.346	4.454	0.740	 	</text></passage><passage><infon key="file">T3.xml</infon><infon key="id">T3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>21365</offset><text>aAdjusted covariates: Model 3 : Model 2 + neutrophils. CI, Confidence interval; LEDVT, lower-extremity deep venous thrombosis; GCS, Glasgow Coma Scale; ICU, intensive care unit; OR, Odds ratios. *p &lt; 0.05.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21571</offset><text>In order to reduce the effects of confounding factors, we conducted a PSM. One-to-one PSM yielded 62 patients, with 31 patients in each group. No statistical significance was detected in the baseline GCS score, baseline ICH volume, length of ICU stays, received treatment, and pulmonary infection between the two groups. Compared to the matched non-LEDVT group, the matched LEDVT group had significantly higher leukocyte counts [11.98 (8.40â13.94) Ã 109 cells/L vs. 6.12 (4.68â12.00) Ã 109 cells/L, p = 0.003; Table 1; Figure 4D]. After PSM, the ROC curve was plotted for leukocytes as a predictor of LEDVT, with an AUC value of 0.722 (95%CI 0.593â0.828, p = 0.001; the sensitivity was 87.10%, and the specificity was 61.29%; Figure 4E). Elevated leukocytes remained independently significant as predictors of LEDVT in elderly patients with primary ICH. We had an interesting finding that a statistically significant correlation was still observed between neutrophils and LEDVT (p = 0.042, Table 1), although neutrophils were included in the PSM.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>22626</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>22637</offset><text>In this study, we applied multivariate and PSM analyses to explore the association of admission leukocyte counts with LEDVT in elderly patients with primary ICH. The significant findings of this study may be summarized as follows: (1) the elevated leukocyte level was a significant independent risk factor of LEDVT; (2) leukocyte counts were inversely associated with the baseline GCS score; (3) leukocyte counts were positively correlated with the baseline ICH volume. The optimal cut-off value of leukocyte counts calculated from the ROC curve to predict LEDVT was 10.22 Ã 109/L in elderly patients with primary ICH. After reducing the effects of confounding factors with a PSM analysis, the matched LEDVT group had significantly higher leukocyte counts than the matched non-LEDVT group. To the best of our knowledge, this is the first study investigating the relationship between admission leukocytes and LEDVT in elderly patients with primary ICH.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>23590</offset><text>Shortly after the onset of acute ICH, the hematoma component triggers an inflammatory response that together with the hematoma, aggravates brain tissue damage and further increases inflammatory cells in peripheral blood. When the blood-brain barrier is compromised after ICH, leukocytes and inflammatory agents can infiltrate into perihematomal areas and eventually cause leukocyte elevation through cerebrospinal fluid circulation. The Spearman correlation analysis revealed a weak positive correlation between leukocytes and the initial ICH volume (r = 0.2396). The correlation analysis can only provide associations and cannot draw inferences regarding a causal relationship between leukocytes and the baseline ICH volume. The previous literature suggested that the higher admission leukocyte count was negatively associated with hematoma expansion, supporting a possible link between acute inflammatory, leukocyte, and coagulation. Results of this study support this inference and extend it, suggesting that inflammation and leukocyte activation are implicated in coagulation after ICH.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>24681</offset><text>Thrombosis is a complex process involving factors related to coagulation and inflammation. Inflammation significantly contributes to LEDVT. Inflammation may affect various stages of the coagulation pathway. Subsequently to acute inflammation, the coagulation cascade is triggered, leading to thrombotic events. Aggregation of leukocytes exacerbates thrombosis. The LEDVT group showed increased leukocyte counts compared with the non-LEDVT group, in this study. Leukocytes interact with platelets, endothelium, and coagulation factors and thus may play a vital role in the pathophysiology of LEDVT by regulating the coagulation system.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>25316</offset><text>A systemic inflammatory response occurs in acute ICH, and peripheral blood leukocytes, particularly neutrophils, are elevated. Activated neutrophils exhibit significant procoagulant properties. Animal models of DVT demonstrate that neutrophils stimulate thrombosis and promote the coagulation process by forming neutrophil extracellular traps, resulting in abundant deep vein thrombosis. In this study, multivariate analysis showed no significant association between neutrophils and LEDVT. Interestingly, although neutrophils were included in the PSM, a statistically significant correlation was still observed between neutrophils and LEDVT after PSM. The inconsistency of our results might be related to the relatively small sample size. More high-quality studies with large sample sizes are needed to clarify this issue.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>26139</offset><text>A complex combination of interactions among the various components in the leukocytes may result in the occurrence of LEDVT. Approximately 50â70% of white blood cells are neutrophils, which comprise human blood's most abundant type of leukocyte. In the view of the mechanism, Yago et al. confirmed that neutrophils cooperatively signal through glycoprotein ligand-1 and CXCR2 to promote DVT. First, neutrophils alter the coagulation balance by significantly expressing and releasing tissue factors, thereby favoring thrombosis. Second, neutrophils indirectly increase active tissue factors, downregulate tissue factor pathway inhibitors, and promote thrombus formation. Third, neutrophil extracellular traps can activate platelets, factor X, and factor XII, enhance thrombin generation, and help stabilize fibrin clots. Activating neutrophils during acute ICH may place the body in a procoagulant state. Fourth, neutrophils in white blood cells are sticky and allow a developing thrombus to adhere to the walls of blood vessels. Sticky neutrophils trigger further endothelial damage and activation of the coagulation cascade, exacerbating thrombus formation. Fifth, although thrombus formation requires neutrophils, monocytes further augment thrombosis by expressing tissue factors. Intimate associations exist between inflammation and thrombosis, with inflammatory states promoting coagulation and thrombus amplifying inflammation. Remarkably, systemic inflammation amplifies the coagulation process, and coagulation can worsen inflammatory progression, especially in elderly patients with ICH, predisposing them to the progression of LEDVT events.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>27790</offset><text>Virchow's triad, first described in 1856, summarizes the numerous risk factors for DVT into three essential elements contributing to thrombosis, venous stasis, vascular injury, and a hypercoagulable state. The clinical conditions following primary ICH most closely associated with LEDVT are fundamentally related to elements of Virchow's triad, including acute critical illness stress, prolonged immobility, advancing age, and invasive endovascular procedures. First, aging is associated with changes in the levels of coagulation factors and fibrinolytic proteins, which activate the coagulation cascade. Older age was the most significant risk factor for developing LEDVT. Second, elderly patients are bedridden for a long time after ICH, especially limb paralysis caused by ICH, which further aggravates blood stasis and eventually forms LEDVT. The previous literature reported a high risk of LEDVT in hospitalized elderly patients with intracerebral hemorrhage, up to 66.7%. The longer they stay still, the higher the risk of developing a LEDVT. Third, during surgery or when intravenous catheters are inserted in patients with ICH, it may damage the vascular endothelium or expose subendothelial factors and reduce blood flow in the blood vessels, thereby activating a series of the coagulation cascade, and ultimately a thrombotic event occurs.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29140</offset><text>Our study revealed significant correlations between the leukocyte levels, baseline GCS score, and initial ICH volume, indicating that the leukocyte levels could reflect ICH severity. Consistent with prior reports, leukocytes are associated with ICH severity. Although the GCS score and initial ICH volume were significantly related to leukocyte levels, the GCS score and initial ICH volume were not risks for LEDVT, suggesting that the GCS score and initial ICH volume were only indicators of the severity of the disease. Bembenek et al. also demonstrated that the National Institute of Health Stroke scale, reflecting acute stroke severity, was not a risk factor for LEDVT.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>29815</offset><text>Limitations</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>29827</offset><text>Our single-center retrospective study has several limitations. First, our study has inherent limitations of this type of design (i.e., the impossibility of establishing definitive causal connections) and might limit the generalizability of the findings. Second, the sample size was relatively small due to the rigorous selection standards. Future studies with a larger sample size would allow for more rigorous validation. Third, only baseline values of leukocyte counts were analyzed rather than the temporal trend. Clinically, LEDVT formation and diagnosis may take a long time. Therefore, attention should be paid to the relationship between the dynamic changes of leukocytes and the occurrence and development of LEDVT. Fourth, it is also worth noting that the actual incidence of LEDVT may be higher than that reported in this study. In neurosurgery wards, lower extremity vascular ultrasonography was not routinely performed weekly, and Doppler ultrasonography was usually performed when the patient was symptomatic. This might have led to an underestimate of the prevalence of LEDVT. Finally, phlebography may diagnose more LEDVT and earlier smaller clots. Due to the severity of the ICH, we did not routinely include venography.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>31064</offset><text>Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>31075</offset><text>Elevated leukocyte upon admission is an independent risk factor of acute LEDVT in elderly patients with primary ICH. Leukocytes are cheap, rapid, convenient, and widely available biomarkers that may improve our ability to identify and stratify early LEDVT risk in clinical practice. Further multicenter randomized studies are needed to investigate the association between leukocyte dynamics and LEDVT.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>31477</offset><text>Data Availability Statement</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>31505</offset><text>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>31627</offset><text>Ethics Statement</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>31644</offset><text>The studies involving human participants were reviewed and approved by the Ethics Committee of Lanzhou University Second Hospital. The ethics committee waived the requirement of written informed consent for participation.</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">title_1</infon><offset>31866</offset><text>Author Contributions</text></passage><passage><infon key="section_type">AUTH_CONT</infon><infon key="type">paragraph</infon><offset>31887</offset><text>GW and WZ designed the study and drafted the manuscript. GW, ZZ, and DeW collected and analyzed data. DoW and RB helped in the statistical analysis and prepared the figures. BH supervised the study and revised the manuscript. GW, BH, and HR initiated and organized this study. All authors reviewed and edited the manuscript and approved the final manuscript.</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">title_1</infon><offset>32246</offset><text>Funding</text></passage><passage><infon key="section_type">ACK_FUND</infon><infon key="type">paragraph</infon><offset>32254</offset><text>This study was supported by the Natural Science Foundation of Gansu Province (Grant Numbers: 20JR5RA336 and GSWSKY2021-006), and the Cuiying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (Grant Number: CY2021-MS-B10).</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>32512</offset><text>Conflict of Interest</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>32533</offset><text>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">title_1</infon><offset>32706</offset><text>Publisher's Note</text></passage><passage><infon key="section_type">COMP_INT</infon><infon key="type">paragraph</infon><offset>32723</offset><text>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>33070</offset><text>References</text></passage><passage><infon key="fpage">1021</infon><infon key="lpage">32</infon><infon key="name_0">surname:Hanley;given-names:DF</infon><infon key="name_1">surname:Thompson;given-names:RE</infon><infon key="name_2">surname:Rosenblum;given-names:M</infon><infon key="name_3">surname:Yenokyan;given-names:G</infon><infon key="name_4">surname:Lane;given-names:K</infon><infon key="name_5">surname:McBee;given-names:N</infon><infon key="pub-id_doi">10.1016/S0140-6736(19)30195-3</infon><infon key="pub-id_pmid">30739747</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">393</infon><infon key="year">2019</infon><offset>33081</offset><text>Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial</text></passage><passage><infon key="fpage">167</infon><infon key="lpage">76</infon><infon key="name_0">surname:van Asch;given-names:CJJ</infon><infon key="name_1">surname:Luitse;given-names:MJA</infon><infon key="name_2">surname:Rinkel;given-names:GJE</infon><infon key="name_3">surname:van der Tweel;given-names:I</infon><infon key="name_4">surname:Algra;given-names:A</infon><infon key="name_5">surname:Klijn;given-names:CJM</infon><infon key="pub-id_doi">10.1016/S1474-4422(09)70340-0</infon><infon key="pub-id_pmid">20056489</infon><infon key="section_type">REF</infon><infon key="source">Lancet Neurol.</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2010</infon><offset>33272</offset><text>Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis</text></passage><passage><infon key="fpage">21</infon><infon key="lpage">6</infon><infon key="name_0">surname:Zubkov;given-names:AY</infon><infon key="name_1">surname:Wijdicks;given-names:EFM</infon><infon key="pub-id_pmid">19367220</infon><infon key="section_type">REF</infon><infon key="source">Rev Neurol Dis</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2009</infon><offset>33441</offset><text>Deep venous thrombosis prophylaxis in cerebral hemorrhage</text></passage><passage><infon key="fpage">64</infon><infon key="lpage">77</infon><infon key="name_0">surname:Khan;given-names:F</infon><infon key="name_1">surname:Tritschler;given-names:T</infon><infon key="name_2">surname:Kahn;given-names:SR</infon><infon key="name_3">surname:Rodger;given-names:MA</infon><infon key="pub-id_doi">10.1016/S0140-6736(20)32658-1</infon><infon key="pub-id_pmid">33984268</infon><infon key="section_type">REF</infon><infon key="source">Lancet.</infon><infon key="type">ref</infon><infon key="volume">398</infon><infon key="year">2021</infon><offset>33499</offset><text>Venous thromboembolism</text></passage><passage><infon key="fpage">1107</infon><infon key="lpage">14</infon><infon key="name_0">surname:Liu;given-names:Z</infon><infon key="name_1">surname:Liu;given-names:D</infon><infon key="name_2">surname:Guo;given-names:ZN</infon><infon key="name_3">surname:Jin;given-names:H</infon><infon key="name_4">surname:Sun;given-names:T</infon><infon key="name_5">surname:Ni;given-names:C</infon><infon key="pub-id_doi">10.2147/PGPM.S321084</infon><infon key="pub-id_pmid">34511981</infon><infon key="section_type">REF</infon><infon key="source">Pharmgenomics Pers Med</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2021</infon><offset>33522</offset><text>Incidence and risk factors of lower-extremity deep vein thrombosis after thrombolysis among patients with acute ischemic stroke</text></passage><passage><infon key="fpage">e1982</infon><infon key="name_0">surname:Khan;given-names:MT</infon><infon key="name_1">surname:Ikram;given-names:A</infon><infon key="name_2">surname:Saeed;given-names:O</infon><infon key="name_3">surname:Afridi;given-names:T</infon><infon key="name_4">surname:Sila;given-names:CA</infon><infon key="name_5">surname:Smith;given-names:MS</infon><infon key="pub-id_doi">10.7759/cureus.1982</infon><infon key="pub-id_pmid">29503776</infon><infon key="section_type">REF</infon><infon key="source">Cureus.</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2017</infon><offset>33650</offset><text>Deep vein thrombosis in acute stroke - a systemic review of the literature</text></passage><passage><infon key="fpage">388</infon><infon key="lpage">92</infon><infon key="name_0">surname:Yamada;given-names:SM</infon><infon key="name_1">surname:Tomita;given-names:Y</infon><infon key="name_2">surname:Murakami;given-names:H</infon><infon key="name_3">surname:Nakane;given-names:M</infon><infon key="pub-id_doi">10.3349/ymj.2016.57.2.388</infon><infon key="pub-id_pmid">26847291</infon><infon key="section_type">REF</infon><infon key="source">Yonsei Med J.</infon><infon key="type">ref</infon><infon key="volume">57</infon><infon key="year">2016</infon><offset>33725</offset><text>Deep vein thrombosis in the lower extremities in comatose elderly patients with acute neurological diseases</text></passage><passage><infon key="fpage">1076029619868534</infon><infon key="name_0">surname:Wang;given-names:Y</infon><infon key="name_1">surname:Shi;given-names:Y</infon><infon key="name_2">surname:Dong;given-names:Y</infon><infon key="name_3">surname:Dong;given-names:Q</infon><infon key="name_4">surname:Ye;given-names:T</infon><infon key="name_5">surname:Fang;given-names:K</infon><infon key="pub-id_doi">10.1177/1076029619868534</infon><infon key="pub-id_pmid">31434499</infon><infon key="section_type">REF</infon><infon key="source">Clin Appl Thromb Hemost.</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2019</infon><offset>33833</offset><text>Clinical risk factors of asymptomatic deep venous thrombosis in patients with acute stroke</text></passage><passage><infon key="fpage">8260487</infon><infon key="name_0">surname:Li;given-names:Q</infon><infon key="name_1">surname:Dai;given-names:B</infon><infon key="name_2">surname:Yao;given-names:Y</infon><infon key="name_3">surname:Song;given-names:K</infon><infon key="name_4">surname:Chen;given-names:D</infon><infon key="name_5">surname:Jiang;given-names:Q</infon><infon key="pub-id_doi">10.1155/2017/8260487</infon><infon key="pub-id_pmid">28612028</infon><infon key="section_type">REF</infon><infon key="source">Biomed Res Int.</infon><infon key="type">ref</infon><infon key="volume">2017</infon><infon key="year">2017</infon><offset>33924</offset><text>Chronic kidney dysfunction can increase the risk of deep vein thrombosis after total hip and knee arthroplasty</text></passage><passage><infon key="fpage">S276</infon><infon key="lpage">84</infon><infon key="name_0">surname:Stone;given-names:J</infon><infon key="name_1">surname:Hangge;given-names:P</infon><infon key="name_2">surname:Albadawi;given-names:H</infon><infon key="name_3">surname:Wallace;given-names:A</infon><infon key="name_4">surname:Shamoun;given-names:F</infon><infon key="name_5">surname:Knuttien;given-names:MG</infon><infon key="pub-id_doi">10.21037/cdt.2017.09.01</infon><infon key="pub-id_pmid">29399531</infon><infon key="section_type">REF</infon><infon key="source">Cardiovasc Diagn Ther.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2017</infon><offset>34035</offset><text>Deep vein thrombosis: pathogenesis, diagnosis, and medical management</text></passage><passage><infon key="fpage">225</infon><infon key="lpage">9</infon><infon key="name_0">surname:Esmon;given-names:CT</infon><infon key="pub-id_doi">10.1016/j.blre.2009.07.002</infon><infon key="pub-id_pmid">19683659</infon><infon key="section_type">REF</infon><infon key="source">Blood Rev.</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2009</infon><offset>34105</offset><text>Basic mechanisms and pathogenesis of venous thrombosis</text></passage><passage><infon key="fpage">171</infon><infon key="lpage">7</infon><infon key="name_0">surname:Seo;given-names:WW</infon><infon key="name_1">surname:Park;given-names:MS</infon><infon key="name_2">surname:Kim;given-names:SE</infon><infon key="name_3">surname:Lee;given-names:JH</infon><infon key="name_4">surname:Park;given-names:DG</infon><infon key="name_5">surname:Han;given-names:KR</infon><infon key="pub-id_doi">10.1055/s-0039-1694043</infon><infon key="pub-id_pmid">31394586</infon><infon key="section_type">REF</infon><infon key="source">J Knee Surg</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2021</infon><offset>34160</offset><text>Neutrophil-lymphocyte ratio as a predictor of venous thromboembolism after total knee replacement</text></passage><passage><infon key="fpage">143</infon><infon key="lpage">7</infon><infon key="name_0">surname:Ming;given-names:L</infon><infon key="name_1">surname:Jiang;given-names:Z</infon><infon key="name_2">surname:Ma;given-names:J</infon><infon key="name_3">surname:Wang;given-names:Q</infon><infon key="name_4">surname:Wu;given-names:F</infon><infon key="name_5">surname:Ping;given-names:J</infon><infon key="pub-id_doi">10.1024/0301-1526/a000683</infon><infon key="pub-id_pmid">29325504</infon><infon key="section_type">REF</infon><infon key="source">Vasa.</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">2018</infon><offset>34258</offset><text>Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and platelet indices in patients with acute deep vein thrombosis</text></passage><passage><infon key="fpage">3715</infon><infon key="lpage">21</infon><infon key="name_0">surname:Wen;given-names:H</infon><infon key="name_1">surname:Chen;given-names:Y</infon><infon key="pub-id_doi">10.1007/s10072-020-05007-y</infon><infon key="pub-id_pmid">33443669</infon><infon key="section_type">REF</infon><infon key="source">Neurol Sci.</infon><infon key="type">ref</infon><infon key="volume">42</infon><infon key="year">2021</infon><offset>34385</offset><text>The predictive value of platelet to lymphocyte ratio and D-dimer to fibrinogen ratio combined with WELLS score on lower extremity deep vein thrombosis in young patients with cerebral hemorrhage</text></passage><passage><infon key="fpage">1473</infon><infon key="lpage">8</infon><infon key="name_0">surname:Morotti;given-names:A</infon><infon key="name_1">surname:Phuah;given-names:CL</infon><infon key="name_2">surname:Anderson;given-names:CD</infon><infon key="name_3">surname:Jessel;given-names:MJ</infon><infon key="name_4">surname:Schwab;given-names:K</infon><infon key="name_5">surname:Ayres;given-names:AM</infon><infon key="pub-id_doi">10.1161/STROKEAHA.116.013176</infon><infon key="pub-id_pmid">27103016</infon><infon key="section_type">REF</infon><infon key="source">Stroke</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">2016</infon><offset>34579</offset><text>Leukocyte count and intracerebral hemorrhage expansion</text></passage><passage><infon key="fpage">417</infon><infon key="lpage">30</infon><infon key="name_0">surname:Esmon;given-names:CT</infon><infon key="pub-id_doi">10.1111/j.1365-2141.2005.05753.x</infon><infon key="pub-id_pmid">16281932</infon><infon key="section_type">REF</infon><infon key="source">Br J Haematol</infon><infon key="type">ref</infon><infon key="volume">131</infon><infon key="year">2005</infon><offset>34634</offset><text>The interactions between inflammation and coagulation</text></passage><passage><infon key="fpage">746</infon><infon key="lpage">56</infon><infon key="name_0">surname:McEver;given-names:RP</infon><infon key="pub-id_doi">10.1055/s-0037-1616128</infon><infon key="pub-id_pmid">11583304</infon><infon key="section_type">REF</infon><infon key="source">Thromb Haemost.</infon><infon key="type">ref</infon><infon key="volume">86</infon><infon key="year">2001</infon><offset>34688</offset><text>Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation</text></passage><passage><infon key="fpage">e1996</infon><infon key="lpage">2004</infon><infon key="name_0">surname:Li;given-names:Y</infon><infon key="name_1">surname:Li;given-names:Y</infon><infon key="name_2">surname:Gurol;given-names:ME</infon><infon key="name_3">surname:Liu;given-names:Y</infon><infon key="name_4">surname:Yang;given-names:P</infon><infon key="name_5">surname:Shi;given-names:J</infon><infon key="pub-id_doi">10.1212/WNL.0000000000009407</infon><infon key="pub-id_pmid">32277057</infon><infon key="section_type">REF</infon><infon key="source">Neurology.</infon><infon key="type">ref</infon><infon key="volume">94</infon><infon key="year">2020</infon><offset>34791</offset><text>In utero exposure to the great chinese famine and risk of intracerebral hemorrhage in midlife</text></passage><passage><infon key="fpage">1440</infon><infon key="lpage">7</infon><infon key="name_0">surname:Boulouis;given-names:G</infon><infon key="name_1">surname:van Etten;given-names:ES</infon><infon key="name_2">surname:Charidimou;given-names:A</infon><infon key="name_3">surname:Auriel;given-names:E</infon><infon key="name_4">surname:Morotti;given-names:A</infon><infon key="name_5">surname:Pasi;given-names:M</infon><infon key="pub-id_doi">10.1001/jamaneurol.2016.2619</infon><infon key="pub-id_pmid">27723863</infon><infon key="section_type">REF</infon><infon key="source">JAMA Neurol.</infon><infon key="type">ref</infon><infon key="volume">73</infon><infon key="year">2016</infon><offset>34885</offset><text>Association of key magnetic resonance imaging markers of cerebral small vessel disease with hematoma volume and expansion in patients with lobar and deep intracerebral hemorrhage</text></passage><passage><infon key="fpage">1559</infon><infon key="lpage">66</infon><infon key="name_0">surname:Insuwanno;given-names:W</infon><infon key="name_1">surname:Kiratisin;given-names:P</infon><infon key="name_2">surname:Jitmuang;given-names:A</infon><infon key="pub-id_doi">10.2147/IDR.S253949</infon><infon key="pub-id_pmid">32547125</infon><infon key="section_type">REF</infon><infon key="source">Infect Drug Resist.</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2020</infon><offset>35064</offset><text>Stenotrophomonas maltophilia Infections: clinical characteristics and factors associated with mortality of hospitalized patients</text></passage><passage><infon key="fpage">1202</infon><infon key="lpage">9</infon><infon key="name_0">surname:Kishore;given-names:AK</infon><infon key="name_1">surname:Vail;given-names:A</infon><infon key="name_2">surname:Chamorro;given-names:A</infon><infon key="name_3">surname:Garau;given-names:J</infon><infon key="name_4">surname:Hopkins;given-names:SJ</infon><infon key="name_5">surname:Di Napoli;given-names:M</infon><infon key="pub-id_doi">10.1161/STROKEAHA.114.007843</infon><infon key="pub-id_pmid">25858238</infon><infon key="section_type">REF</infon><infon key="source">Stroke.</infon><infon key="type">ref</infon><infon key="volume">46</infon><infon key="year">2015</infon><offset>35193</offset><text>How is pneumonia diagnosed in clinical stroke research? a systematic review and meta-analysis</text></passage><passage><infon key="fpage">55</infon><infon key="lpage">9</infon><infon key="name_0">surname:Wang;given-names:Q</infon><infon key="name_1">surname:Liu;given-names:Y</infon><infon key="name_2">surname:Han;given-names:L</infon><infon key="name_3">surname:He;given-names:F</infon><infon key="name_4">surname:Cai;given-names:N</infon><infon key="name_5">surname:Zhang;given-names:Q</infon><infon key="pub-id_doi">10.1016/j.ajem.2020.12.036</infon><infon key="pub-id_pmid">33387929</infon><infon key="section_type">REF</infon><infon key="source">Am J Emerg Med.</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2021</infon><offset>35287</offset><text>Risk factors for acute stroke-associated pneumonia and prediction of neutrophil-to-lymphocyte ratios</text></passage><passage><infon key="fpage">734</infon><infon key="lpage">9</infon><infon key="name_0">surname:Shackford;given-names:SR</infon><infon key="name_1">surname:Cipolle;given-names:MD</infon><infon key="name_2">surname:Badiee;given-names:J</infon><infon key="name_3">surname:Mosby;given-names:DL</infon><infon key="name_4">surname:Knudson;given-names:MM</infon><infon key="name_5">surname:Lewis;given-names:PR</infon><infon key="pub-id_doi">10.1097/TA.0000000000001009</infon><infon key="pub-id_pmid">26891155</infon><infon key="section_type">REF</infon><infon key="source">J Trauma Acute Care Surg</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">2016</infon><offset>35388</offset><text>Determining the magnitude of surveillance bias in the assessment of lower extremity deep venous thrombosis: a prospective observational study of two centers</text></passage><passage><infon key="fpage">59</infon><infon key="lpage">68</infon><infon key="name_0">surname:Couturaud;given-names:F</infon><infon key="name_1">surname:Bertoletti;given-names:L</infon><infon key="name_2">surname:Pastre;given-names:J</infon><infon key="name_3">surname:Roy;given-names:PM</infon><infon key="name_4">surname:Le Mao;given-names:R</infon><infon key="name_5">surname:Gagnadoux;given-names:F</infon><infon key="pub-id_doi">10.1001/jama.2020.23567</infon><infon key="pub-id_pmid">33399840</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">325</infon><infon key="year">2021</infon><offset>35545</offset><text>Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms</text></passage><passage><infon key="fpage">724</infon><infon key="name_0">surname:Wang;given-names:J</infon><infon key="name_1">surname:Hu;given-names:B</infon><infon key="name_2">surname:Li;given-names:T</infon><infon key="name_3">surname:Miao;given-names:J</infon><infon key="name_4">surname:Zhang;given-names:W</infon><infon key="name_5">surname:Chen;given-names:S</infon><infon key="pub-id_doi">10.21037/atm.2019.12.24</infon><infon key="pub-id_pmid">32042740</infon><infon key="section_type">REF</infon><infon key="source">Ann Transl Med.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2019</infon><offset>35660</offset><text>The EGFR-rearranged adenocarcinoma is associated with a high rate of venous thromboembolism</text></passage><passage><infon key="fpage">1244</infon><infon key="lpage">8</infon><infon key="name_0">surname:Gary;given-names:T</infon><infon key="name_1">surname:Belaj;given-names:K</infon><infon key="name_2">surname:Steidl;given-names:K</infon><infon key="name_3">surname:Pichler;given-names:M</infon><infon key="name_4">surname:Eisner;given-names:F</infon><infon key="name_5">surname:Stoger;given-names:H</infon><infon key="pub-id_doi">10.1038/bjc.2012.401</infon><infon key="pub-id_pmid">22968652</infon><infon key="section_type">REF</infon><infon key="source">Br J Cancer.</infon><infon key="type">ref</infon><infon key="volume">107</infon><infon key="year">2012</infon><offset>35752</offset><text>Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival</text></passage><passage><infon key="fpage">2212</infon><infon key="lpage">22</infon><infon key="name_0">surname:Martinod;given-names:E</infon><infon key="name_1">surname:Chouahnia;given-names:K</infon><infon key="name_2">surname:Radu;given-names:DM</infon><infon key="name_3">surname:Joudiou;given-names:P</infon><infon key="name_4">surname:Uzunhan;given-names:Y</infon><infon key="name_5">surname:Bensidhoum;given-names:M</infon><infon key="pub-id_doi">10.1001/jama.2018.4653</infon><infon key="pub-id_pmid">29800033</infon><infon key="section_type">REF</infon><infon key="source">JAMA.</infon><infon key="type">ref</infon><infon key="volume">319</infon><infon key="year">2018</infon><offset>35879</offset><text>Feasibility of bioengineered tracheal and bronchial reconstruction using stented aortic matrices</text></passage><passage><infon key="fpage">288</infon><infon key="lpage">97</infon><infon key="name_0">surname:Askenase;given-names:MH</infon><infon key="name_1">surname:Sansing;given-names:LH</infon><infon key="pub-id_doi">10.1055/s-0036-1582132</infon><infon key="pub-id_pmid">27214704</infon><infon key="section_type">REF</infon><infon key="source">Semin Neurol.</infon><infon key="type">ref</infon><infon key="volume">36</infon><infon key="year">2016</infon><offset>35976</offset><text>Stages of the inflammatory response in pathology and tissue repair after intracerebral hemorrhage</text></passage><passage><infon key="fpage">475</infon><infon key="name_0">surname:Zhao;given-names:XJ</infon><infon key="name_1">surname:Li;given-names:QX</infon><infon key="name_2">surname:Chang;given-names:LS</infon><infon key="name_3">surname:Zhang;given-names:J</infon><infon key="name_4">surname:Wang;given-names:DL</infon><infon key="name_5">surname:Fan;given-names:HY</infon><infon key="pub-id_doi">10.3389/fneur.2019.00475</infon><infon key="pub-id_pmid">31293492</infon><infon key="section_type">REF</infon><infon key="source">Front Neurol.</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2019</infon><offset>36074</offset><text>Evaluation of the application of APACHE II combined with NIHSS score in the short-term prognosis of acute cerebral hemorrhage patient</text></passage><passage><infon key="fpage">158</infon><infon key="lpage">64</infon><infon key="name_0">surname:Brouwers;given-names:HB</infon><infon key="name_1">surname:Chang;given-names:Y</infon><infon key="name_2">surname:Falcone;given-names:GJ</infon><infon key="name_3">surname:Cai;given-names:X</infon><infon key="name_4">surname:Ayres;given-names:AM</infon><infon key="name_5">surname:Battey;given-names:TW</infon><infon key="pub-id_doi">10.1001/jamaneurol.2013.5433</infon><infon key="pub-id_pmid">24366060</infon><infon key="section_type">REF</infon><infon key="source">JAMA Neurol.</infon><infon key="type">ref</infon><infon key="volume">71</infon><infon key="year">2014</infon><offset>36208</offset><text>Predicting hematoma expansion after primary intracerebral hemorrhage</text></passage><passage><infon key="fpage">1451</infon><infon key="lpage">7</infon><infon key="name_0">surname:Yaghi;given-names:S</infon><infon key="name_1">surname:Boehme;given-names:AK</infon><infon key="name_2">surname:Dibu;given-names:J</infon><infon key="name_3">surname:Leon Guerrero;given-names:CR</infon><infon key="name_4">surname:Ali;given-names:S</infon><infon key="name_5">surname:Martin-Schild;given-names:S</infon><infon key="pub-id_doi">10.1001/jamaneurol.2015.2371</infon><infon key="pub-id_pmid">26501741</infon><infon key="section_type">REF</infon><infon key="source">JAMA Neurol.</infon><infon key="type">ref</infon><infon key="volume">72</infon><infon key="year">2015</infon><offset>36277</offset><text>Treatment and outcome of thrombolysis-related hemorrhage: a multicenter retrospective study</text></passage><passage><infon key="fpage">1257</infon><infon key="lpage">68</infon><infon key="name_0">surname:Cordonnier;given-names:C</infon><infon key="name_1">surname:Demchuk;given-names:A</infon><infon key="name_2">surname:Ziai;given-names:W</infon><infon key="name_3">surname:Anderson;given-names:CS</infon><infon key="pub-id_doi">10.1016/S0140-6736(18)31878-6</infon><infon key="pub-id_pmid">30319113</infon><infon key="section_type">REF</infon><infon key="source">Lancet.</infon><infon key="type">ref</infon><infon key="volume">392</infon><infon key="year">2018</infon><offset>36369</offset><text>Intracerebral haemorrhage: current approaches to acute management</text></passage><passage><infon key="fpage">104866</infon><infon key="name_0">surname:Liu;given-names:XC</infon><infon key="name_1">surname:Chen;given-names:XW</infon><infon key="name_2">surname:Li;given-names:ZL</infon><infon key="name_3">surname:Wang;given-names:SC</infon><infon key="name_4">surname:Chen;given-names:C</infon><infon key="pub-id_doi">10.1016/j.jstrokecerebrovasdis.2020.104866</infon><infon key="pub-id_pmid">32404283</infon><infon key="section_type">REF</infon><infon key="source">J Stroke Cerebrovasc Dis</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2020</infon><offset>36435</offset><text>Anatomical distribution of lower-extremity deep venous thrombosis in patients with acute stroke</text></passage><passage><infon key="fpage">1426</infon><infon key="lpage">36</infon><infon key="name_0">surname:Yago;given-names:T</infon><infon key="name_1">surname:Liu;given-names:Z</infon><infon key="name_2">surname:Ahamed;given-names:J</infon><infon key="name_3">surname:McEver;given-names:RP</infon><infon key="pub-id_doi">10.1182/blood-2018-05-850859</infon><infon key="pub-id_pmid">30068506</infon><infon key="section_type">REF</infon><infon key="source">Blood.</infon><infon key="type">ref</infon><infon key="volume">132</infon><infon key="year">2018</infon><offset>36531</offset><text>Cooperative PSGL-1 and CXCR2 signaling in neutrophils promotes deep vein thrombosis in mice</text></passage><passage><infon key="fpage">938</infon><infon key="lpage">49</infon><infon key="name_0">surname:Furie;given-names:B</infon><infon key="name_1">surname:Furie;given-names:BC</infon><infon key="pub-id_doi">10.1056/NEJMra0801082</infon><infon key="pub-id_pmid">18753650</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">359</infon><infon key="year">2008</infon><offset>36623</offset><text>Mechanisms of thrombus formation</text></passage><passage><infon key="fpage">753</infon><infon key="lpage">62</infon><infon key="name_0">surname:Swystun;given-names:LL</infon><infon key="name_1">surname:Liaw;given-names:PC</infon><infon key="pub-id_doi">10.1182/blood-2016-05-718114</infon><infon key="pub-id_pmid">27354721</infon><infon key="section_type">REF</infon><infon key="source">Blood.</infon><infon key="type">ref</infon><infon key="volume">128</infon><infon key="year">2016</infon><offset>36656</offset><text>The role of leukocytes in thrombosis</text></passage><passage><infon key="fpage">15559</infon><infon key="name_0">surname:Wang;given-names:Y</infon><infon key="name_1">surname:Gao;given-names:H</infon><infon key="name_2">surname:Shi;given-names:C</infon><infon key="name_3">surname:Erhardt;given-names:PW</infon><infon key="name_4">surname:Pavlovsky;given-names:A</infon><infon key="name_5">surname:Soloviev;given-names:DA</infon><infon key="pub-id_doi">10.1038/ncomms15559</infon><infon key="pub-id_pmid">28555620</infon><infon key="section_type">REF</infon><infon key="source">Nat Commun.</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2017</infon><offset>36693</offset><text>Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIbalpha</text></passage><passage><infon key="fpage">1777</infon><infon key="lpage">83</infon><infon key="name_0">surname:Fuchs;given-names:TA</infon><infon key="name_1">surname:Brill;given-names:A</infon><infon key="name_2">surname:Wagner;given-names:DD</infon><infon key="pub-id_doi">10.1161/ATVBAHA.111.242859</infon><infon key="pub-id_pmid">22652600</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb Vasc Biol.</infon><infon key="type">ref</infon><infon key="volume">32</infon><infon key="year">2012</infon><offset>36779</offset><text>Neutrophil extracellular trap (NET) impact on deep vein thrombosis</text></passage><passage><infon key="fpage">1323</infon><infon key="lpage">30</infon><infon key="name_0">surname:Maugeri;given-names:N</infon><infon key="name_1">surname:Brambilla;given-names:M</infon><infon key="name_2">surname:Camera;given-names:M</infon><infon key="name_3">surname:Carbone;given-names:A</infon><infon key="name_4">surname:Tremoli;given-names:E</infon><infon key="name_5">surname:Donati;given-names:MB</infon><infon key="pub-id_doi">10.1111/j.1538-7836.2006.01968.x</infon><infon key="pub-id_pmid">16706978</infon><infon key="section_type">REF</infon><infon key="source">J Thromb Haemos.</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2006</infon><offset>36846</offset><text>Human polymorphonuclear leukocytes produce and express functional tissue factor upon stimulation</text></passage><passage><infon key="fpage">1977</infon><infon key="lpage">84</infon><infon key="name_0">surname:Gould;given-names:TJ</infon><infon key="name_1">surname:Vu;given-names:TT</infon><infon key="name_2">surname:Swystun;given-names:LL</infon><infon key="name_3">surname:Dwivedi;given-names:DJ</infon><infon key="name_4">surname:Mai;given-names:SH</infon><infon key="name_5">surname:Weitz;given-names:JI</infon><infon key="pub-id_doi">10.1161/ATVBAHA.114.304114</infon><infon key="pub-id_pmid">25012129</infon><infon key="section_type">REF</infon><infon key="source">Arterioscler Thromb Vasc Biol.</infon><infon key="type">ref</infon><infon key="volume">34</infon><infon key="year">2014</infon><offset>36943</offset><text>Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms</text></passage><passage><infon key="fpage">887</infon><infon key="lpage">96</infon><infon key="name_0">surname:Massberg;given-names:S</infon><infon key="name_1">surname:Grahl;given-names:L</infon><infon key="name_2">surname:von Bruehl;given-names:ML</infon><infon key="name_3">surname:Manukyan;given-names:D</infon><infon key="name_4">surname:Pfeiler;given-names:S</infon><infon key="name_5">surname:Goosmann;given-names:C</infon><infon key="pub-id_doi">10.1038/nm.2184</infon><infon key="pub-id_pmid">20676107</infon><infon key="section_type">REF</infon><infon key="source">Nat Med.</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2010</infon><offset>37065</offset><text>Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases</text></passage><passage><infon key="fpage">447</infon><infon key="lpage">56</infon><infon key="name_0">surname:Steger;given-names:CM</infon><infon key="name_1">surname:Mayr;given-names:T</infon><infon key="name_2">surname:Bonaros;given-names:N</infon><infon key="name_3">surname:Bonatti;given-names:J</infon><infon key="name_4">surname:Schachner;given-names:T</infon><infon key="pub-id_doi">10.1111/iep.12215</infon><infon key="pub-id_pmid">28004436</infon><infon key="section_type">REF</infon><infon key="source">Int J Exp Pathol.</infon><infon key="type">ref</infon><infon key="volume">97</infon><infon key="year">2016</infon><offset>37152</offset><text>Vein graft disease in a knockout mouse model of hyperhomocysteinaemia</text></passage><passage><infon key="fpage">15377</infon><infon key="name_0">surname:Boettcher;given-names:M</infon><infon key="name_1">surname:Eschenburg;given-names:G</infon><infon key="name_2">surname:Mietzsch;given-names:S</infon><infon key="name_3">surname:Jimenez-Alcazar;given-names:M</infon><infon key="name_4">surname:Klinke;given-names:M</infon><infon key="name_5">surname:Vincent;given-names:D</infon><infon key="pub-id_doi">10.1038/s41598-017-15807-6</infon><infon key="pub-id_pmid">29133856</infon><infon key="section_type">REF</infon><infon key="source">Sci Rep.</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2017</infon><offset>37222</offset><text>Therapeutic targeting of extracellular DNA improves the outcome of intestinal ischemic reperfusion injury in neonatal rats</text></passage><passage><infon key="fpage">10509</infon><infon key="lpage">16</infon><infon key="name_0">surname:Song;given-names:H</infon><infon key="name_1">surname:Men;given-names:H</infon><infon key="name_2">surname:Song;given-names:C</infon><infon key="name_3">surname:Feng;given-names:H</infon><infon key="name_4">surname:Tan;given-names:H</infon><infon key="name_5">surname:Zuo;given-names:S</infon><infon key="pub-id_pmid">34650721</infon><infon key="section_type">REF</infon><infon key="source">Am J Transl Res.</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2021</infon><offset>37345</offset><text>Low-molecular-weight heparin reduces the formation of lower limb deep venous thrombosis in patients with hypertensive intracerebral hemorrhage</text></passage><passage><infon key="fpage">567</infon><infon key="lpage">74</infon><infon key="name_0">surname:Shaikhouni;given-names:A</infon><infon key="name_1">surname:Baum;given-names:J</infon><infon key="name_2">surname:Lonser;given-names:RR</infon><infon key="pub-id_doi">10.1016/j.nec.2018.06.010</infon><infon key="pub-id_pmid">30223969</infon><infon key="section_type">REF</infon><infon key="source">Neurosurg Clin N Am.</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2018</infon><offset>37488</offset><text>Deep vein thrombosis prophylaxis in the neurosurgical patient</text></passage><passage><infon key="fpage">893</infon><infon key="lpage">8</infon><infon key="name_0">surname:Paciaroni;given-names:M</infon><infon key="name_1">surname:Agnelli;given-names:G</infon><infon key="name_2">surname:Venti;given-names:M</infon><infon key="name_3">surname:Alberti;given-names:A</infon><infon key="name_4">surname:Acciarresi;given-names:M</infon><infon key="name_5">surname:Caso;given-names:V</infon><infon key="pub-id_doi">10.1111/j.1538-7836.2011.04241.x</infon><infon key="pub-id_pmid">21324058</infon><infon key="section_type">REF</infon><infon key="source">J Thromb Haemost</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2011</infon><offset>37550</offset><text>Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies</text></passage><passage><infon key="fpage">175</infon><infon key="lpage">9</infon><infon key="name_0">surname:Konh;given-names:KH</infon><infon key="name_1">surname:Chua;given-names:SG</infon><infon key="name_2">surname:Earnest;given-names:A</infon><infon key="pub-id_doi">10.1111/j.1747-4949.2009.00278.x</infon><infon key="pub-id_pmid">19659817</infon><infon key="section_type">REF</infon><infon key="source">Int J Stroke.</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2009</infon><offset>37714</offset><text>Deep vein thrombosis in stroke patients admitted to a rehabilitation unit in Singapore</text></passage><passage><infon key="fpage">e5827</infon><infon key="name_0">surname:Farr;given-names:S</infon><infon key="name_1">surname:Toor;given-names:H</infon><infon key="name_2">surname:Patchana;given-names:T</infon><infon key="name_3">surname:Podkovik;given-names:S</infon><infon key="name_4">surname:Wiginton;given-names:JGt</infon><infon key="name_5">surname:Sweiss;given-names:R</infon><infon key="pub-id_doi">10.7759/cureus.5827</infon><infon key="pub-id_pmid">31754562</infon><infon key="section_type">REF</infon><infon key="source">Cureus</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2019</infon><offset>37801</offset><text>Risks, benefits, and the optimal time to resume deep vein thrombosis prophylaxis in patients with intracranial hemorrhage</text></passage><passage><infon key="fpage">258</infon><infon key="lpage">64</infon><infon key="name_0">surname:Bembenek;given-names:JP</infon><infon key="name_1">surname:Karlinski;given-names:M</infon><infon key="name_2">surname:Kobayashi;given-names:A</infon><infon key="name_3">surname:Czlonkowska;given-names:A</infon><infon key="pub-id_doi">10.1177/1076029611424575</infon><infon key="pub-id_pmid">22067545</infon><infon key="section_type">REF</infon><infon key="source">Clin Appl Thromb Hemost.</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2012</infon><offset>37923</offset><text>Deep venous thrombosis in acute stroke patients</text></passage></document>
</collection>